Pharmacokinetic profile of armodafinil in healthy subjects: Pooled analysis of data from three randomized studies

Clinical Drug Investigation

Volumn 29, Issue 2, 2009, Pages 87-100

  Darwish, Mona ^a   Kirby, Mary ^a   Hellriegel, Edward T ^a   Yang, Ronghua ^a   Robertson Jr , Philmore ^a  

^a CEPHALON INC   (United States)

Author keywords

Armodafinil, pharmacokinetics; Central nervous system stimulants, pharmacokinetics; Research and development

Indexed keywords

ARMODAFINIL; DRUG METABOLITE; MODAFINIL ACID; MODAFINIL SULFONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENERGY; FAT INTAKE; FATIGUE; FEMALE; FOOD; FOOD DRUG INTERACTION; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LINEAR REGRESSION ANALYSIS; MALE; NAUSEA; NORMAL HUMAN; PAIN; PHARMACOKINETICS; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; VASODILATATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; BIOLOGICAL AVAILABILITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 58149375824     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/0044011-200929020-00003     Document Type: Article

References (15)

1. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006; 28 (5): 689-706
2. Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med 2007; 101 (3): 616-27
3. Drake C, Walsh J, Roth T. Armodafinil improves sleep latency in patients with shift work sleep disorder [abstract no. 0189]. Sleep 2006; 29 Suppl.: A64
4. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006; 22 (4): 761-74
5. Schwartz JR, Nelson MT, Schwartz ER, et al. Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin Neuropharmacol 2004; 27 (2): 74-9
6. Schwartz JR, Feldman NT, Bogan RK, et al. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol 2003; 26 (5): 252-7
7. Schwartz JR, Feldman NT, Bogan RK. Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. J Neuropsychiatry Clin Neurosci 2005; 17 (3): 405-12
8. Data on file, Cephalon, Inc., West Chester (PA), USA, 1998
9. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999; 39 (1): 30-40
10. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999; 39 (3): 281-8
11. Dinges DF, Arora S, Darwish M, et al. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006; 22 (1): 159-67
12. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Good Clinical Practice: Consolidated Guidance E6(R1). ICH, 1996 [on-line]. Available from URL: http://www.fda.gov/cder/guidance/959fnl.pdf [Accessed 2008 Nov 25]
13. United States Food and Drug Administration, Center for Drug Evaluation and Research. Coding symbols for thesaurus of adverse reaction terms. 5th ed. Rockville (MD): Department of Health and Human Services, Center for Drug Evaluation and Research, Office of Epidemiology Biostatistics, 1995
14. International Federation of Pharmaceutical Manufacturers Associations. Medical dictionary for regulatory activities (MedDRA): version 7.0. Chantilly (VA): MedDRA MSSO, 2004 Mar
15. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000; 17 (10): 1278-83